Group 1 - The core point of the article is that Atnini Group has signed a strategic cooperation agreement with Guangzhou Baiyunshan Weiyi Industrial Co., Ltd. to jointly develop products in the health sector and expand market reach, with a cooperation period of one year [1][2] - The strategic cooperation will focus on joint product development in areas such as natural plant extracts, functional health products, and personal care products [1] - Baiyunshan Weiyi will provide brand marketing support, including brand strategy, trademark licensing, and technical consulting for sales and market promotion related to health products [1] Group 2 - The cooperation aligns with Atnini Group's business development strategy and long-term layout in the health industry, aiming to leverage the strengths of both companies for synergistic effects [2] - This partnership is expected to enrich Atnini Group's product portfolio and enhance its core competitiveness in the health sector, potentially opening new revenue streams [2] - The board of directors believes that the agreement with Baiyunshan Weiyi is in the overall interest of the company and its shareholders [2]

Group 1 - The core point of the article is the strategic cooperation agreement signed between Yatani Group and Guangzhou Baiyunshan Weiyi Industrial Co., Ltd. to jointly develop products in the health sector and expand market reach [1][2] Group 2 - The strategic cooperation agreement is set for a duration of one year and focuses on joint product development in areas such as natural plant extracts, functional health products, and personal care products [1] - The collaboration aims to leverage Baiyunshan Weiyi's brand marketing support, including brand strategy, trademark licensing, and technical consulting for sales and market promotion [1] - This partnership aligns with the company's strategy to expand its beauty and health product sales, enhancing its core competitiveness in the health sector and opening new revenue streams [2]

Core Viewpoint - The strategic cooperation agreement between Yatani Group and Guangzhou Baiyunshan Weiyi Industrial Co., Ltd. aims to jointly develop products in the health sector and expand market reach, with a focus on innovation and international marketing support [1][2]. Group 1: Strategic Cooperation Details - The cooperation agreement is set for one year, focusing on joint research and development of products in the health sector, including natural plant extracts, functional health products, and personal care items [1]. - Baiyunshan Weiyi will provide brand marketing support, including brand strategy, trademark licensing, and technical consulting for sales and market promotion related to health products [1]. Group 2: Business Development Strategy - The partnership aligns with the company's strategy to expand its beauty and health product sales, enhancing its long-term positioning in the health industry [2]. - The board believes that this collaboration will leverage the company's international market advantages and Baiyunshan Weiyi's technical and brand strengths, creating synergies that could enrich the product portfolio and open new revenue streams [2].

本 公 告 乃 由 雅 天 妮 集 團 有 限 公 司（「本公司」，連 同 其 附 屬 公 司 統 稱「本集團」）自 願 向 本 公 司 股 東（「股 東」）及 本 公 司 潛 在 投 資 者 作 出。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 Artini Holdings Limited 雅天妮集團有限公司 （於百慕達註冊成立之有限公司） （股份代號：789） 自願公告 關於與白雲山維一簽訂戰略合作協議 本 公 司 董 事（「董 事」）會（「董事會」）欣 然 公 告，於 二 零 二 五 年 九 月 十 九 日，本 公 司 與 廣 州 白 雲 山 維 一 實 業 股 份 有 限 公 司（「白雲山維一」）簽 署 了 一 份 戰 略 合 作 協 議 （「合作協議」），旨 在 共 同 研 發 大 健 康 領 域 產 品 及 拓 展 市 場（「戰略合作」）。合 作 期 限 為 一 年。 白 雲 ...

Core Viewpoint - The stock of Kingdawei has experienced fluctuations, with a recent decline of 2.04% on September 18, 2023, while the company has shown a year-to-date increase of 30.61% in stock price [1] Financial Performance - For the first half of 2025, Kingdawei reported a revenue of 1.728 billion yuan, representing a year-on-year growth of 13.46%, and a net profit attributable to shareholders of 247 million yuan, which is a significant increase of 90.12% [2] - Cumulatively, since its A-share listing, Kingdawei has distributed a total of 2.761 billion yuan in dividends, with 488 million yuan distributed over the past three years [3] Shareholder Information - As of June 30, 2025, the number of shareholders for Kingdawei is 40,700, a decrease of 4.30% from the previous period, while the average circulating shares per person increased by 4.50% to 14,976 shares [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which increased its holdings by 1.5915 million shares, and Southern CSI 1000 ETF, which increased its holdings by 521,500 shares [3] Market Activity - On September 18, 2023, Kingdawei's stock price was 19.20 yuan per share, with a trading volume of 145 million yuan and a turnover rate of 1.22%, resulting in a total market capitalization of 11.711 billion yuan [1] - The net outflow of main funds was 11.648 million yuan, with significant selling pressure observed in large orders [1] Business Overview - Kingdawei, established on November 24, 1997, and listed on October 28, 2011, is primarily engaged in the manufacturing of health food and nutritional products, with its main revenue sources being health food (54.57%), coenzyme Q10 series (22.04%), and vitamin A series (11.41%) [1] - The company is classified under the food and beverage industry, specifically in food processing and health products [1]

Core Viewpoint - The stock price of Tongchen Beijian has shown fluctuations, with a recent increase of 2.08% to 12.29 CNY per share, while the company faces a decline in revenue and net profit for the first half of 2025 compared to the previous year [1][2]. Group 1: Stock Performance - As of September 18, Tongchen Beijian's stock price increased by 2.08%, reaching 12.29 CNY per share, with a trading volume of 96.62 million CNY and a turnover rate of 0.71% [1]. - The company has experienced a 5.10% increase in stock price year-to-date, a 0.33% increase over the last five trading days, a 1.29% decrease over the last 20 days, and a 9.63% increase over the last 60 days [1]. Group 2: Financial Performance - For the first half of 2025, Tongchen Beijian reported a revenue of 3.532 billion CNY, a year-on-year decrease of 23.43%, and a net profit attributable to shareholders of 737 million CNY, down 17.34% year-on-year [2]. - The company has distributed a total of 8.321 billion CNY in dividends since its A-share listing, with 2.429 billion CNY distributed over the last three years [3]. Group 3: Shareholder Information - As of June 30, 2025, the number of shareholders for Tongchen Beijian was 71,200, a decrease of 4.96% from the previous period, with an average of 15,869 circulating shares per shareholder, an increase of 5.22% [2]. - The top ten circulating shareholders include notable ETFs, with E Fund's ChiNext ETF holding 24.5972 million shares, a decrease of 648,400 shares from the previous period [3].

Core Viewpoint - The company, Jindawei, reported that its revenue in the United States is primarily derived from two sources: income from its U.S. subsidiary and exports from its domestic subsidiary, mainly focusing on coenzyme Q10. The company stated that the U.S.-China trade relationship does not significantly impact its operations [1] Group 1 - The U.S. subsidiary's income is largely unaffected by U.S.-China trade tensions [1] - Exports to the U.S. mainly consist of coenzyme Q10, with the majority of raw materials sourced from China [1] - The U.S. is the largest consumer market for coenzyme Q10 globally, indicating strong demand [1] Group 2 - The company's exports to the U.S. are influenced by downstream customer inventory cycles and market supply-demand changes [1] - Currently, the impact of U.S.-China trade relations on the company's operations is minimal [1]

Core Insights - The company, Xianle Health, indicated that by the first half of 2025, the proportion of its advantageous dosage forms will increase, leading to an overall improvement in gross profit margin due to product structure optimization [1] - The gross profit margin and sales ratio of gummy products have both seen a year-on-year increase, while the competitive edge and profitability of soft capsules are expected to enhance as the business scales up [1] Group 1 - The company is implementing lean production and continuous cost reduction strategies, including supplier integration and negotiation, global procurement, and the promotion of preferred materials to achieve systematic cost reductions [1] - The introduction of an intelligent flexible production scheduling system and the establishment of a dynamic capacity matching mechanism have improved equipment and personnel utilization [1] - Continuous efforts to enhance production stability and process improvements have led to reduced material consumption and increased production line efficiency [1] Group 2 - The company is promoting the localization of spare parts to lower manufacturing costs [1]

在保健品行业蓬勃发展的当下，跨境电商已成为品牌拓展全球市场的重要渠道。然而，面对复杂的国际 法规、供应链挑战及生产成本压力，越来越多的保健品企业选择代加工（OEM/ODM）模式切入跨境电 商赛道。为何代加工能成为行业主流选择？本文从专业角度解析其核心优势。 灵活应对市场动态 跨境电商市场变化迅速，消费者需求呈个性化、碎片化趋势。代加工模式赋予品牌方高度灵活性：可根 据销售数据快速调整订单量，避免库存积压；可灵活更换包装设计或配方微调，适配不同区域消费偏 好。代工厂的敏捷生产体系支持"小批量、多批次"订单，帮助品牌降低试错成本，精准捕捉市场机会。 跨境电商需应对多国市场差异化需求，自主研发与生产将面临高昂的设备投入、人力成本及时间成本。 代加工模式通过专业化分工，将生产环节交由经验丰富的工厂完成，品牌方可聚焦市场策略与销售渠 道。代工厂具备成熟的生产线、规模化采购优势及标准化流程，能有效降低单品成本，缩短产品从研发 到上市的周期，提升资金周转效率。 合规与质量的刚性保障 保健品跨境销售需遵循各国严格的食品安全法规（如FDA、CE、欧盟新规等），合规门槛极高。专业 代加工企业通常具备GMP认证、ISO体系等资质， ...

（编辑 姚尧） 证券日报网讯 金达威9月15日在互动平台回答投资者提问时表示，关于NMN，公司会积极与监管机构 进行沟通，跟进国内相关政策法规的最新进展。截至目前，国家卫健委尚未正式公开披露其具体委托进 行NMN作为食品添加剂或保健品原料准入评审的国内科研机构或生产单位名单。公司将继续与国内相 关的行业机构、科研单位保持技术交流与合作，共同推动NMN领域的科学研究。 ...